Shares for Myriad Genetics took a nosedive as pessimism surrounds the company in its fight against a rival’s alleged infringement on Myriad patents, say reports.
The company lost a bid to have its rival’s products blocked while the lawsuit is pending. Myriad is suing Ambry Genetics for allegations the company violated Myriad patents, but US District Judge Robert Shelby said the company is unlikely to emerge successful in the cases.
Reports say there are “substantial questions,” as the judge put it, as to whether the property in question actually constitute a patent.
Reports say the genetics company claims Ambry infringed on patents involving tests that detect breast and ovarian cancer.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Competition Watchdog to Investigate Carlsberg’s £3.3bn Takeover of Britvic
Sep 11, 2024 by
CPI
News Corp Faced Millions in Losses by Moving Away from Google Ads, Ex-Executive Testifies
Sep 10, 2024 by
CPI
EU Faces Critical Innovation Gap, Draghi Report Urges Antitrust Reforms
Sep 10, 2024 by
CPI
Womble Bond Dickinson and Lewis Roca to Merge, Forming 1,300-Lawyer Firm
Sep 10, 2024 by
CPI
Federal Judge Dismisses Antitrust Lawsuit Against Fidelity and Schwab
Sep 10, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Canada & Mexico
Sep 3, 2024 by
CPI
Competitive Convergence: Mexico’s 30-Year Quest for Antitrust Parity with its Northern Neighbor
Sep 3, 2024 by
CPI
Competition and Digital Markets in North America: A Comparative Study of Antitrust Investigations in Mexico and the United States
Sep 3, 2024 by
CPI
Recent Antitrust Development in Mexico: COFECE’s Preliminary Report on Amazon and Mercado Libre
Sep 3, 2024 by
CPI
The Cost of Making COFECE Disappear
Sep 3, 2024 by
CPI